IMMUNA Benefits Muscle Atrophy (Preclinical Data)
Immunis Scientific Advisory Board member, Professor Micah Drummond, published preclinical research in GeroScience supporting that Immunis’ investigational secretome improved muscle mass and strength during disuse and recovery in aged mouse models.
Aged mice received intramuscular injections of IMMUNA (referred to as IMM01-STEM in the publication) during three experimental conditions: ambulation (control), disuse atrophy or recovery from disuse atrophy. Compared to control-treated, aged mice, IMMUNA treatment resulted in greater soleus muscle mass, increased muscle fiber cross-sectional area, and improved grip strength for all three experimental conditions. There was also a decrease in collagen content and an increase in the number of muscle stem cells, indicative of an enhanced muscle remodeling response. Additionally, administration of IMMUNA to rodent muscle cell cultures increased myotube size and enhanced the incorporation of myonuclei into myotubes.
Collectively, these preclinical findings demonstrate that Immunis’ secretome has immunomodulatory effects that enhance muscle size and strength following atrophy. Immunis has been approved by the U.S. Food and Drug Administration to conduct a Phase 1/2a clinical trial investigating IMMUNA on muscle atrophy in patients with knee osteoarthritis (KOA).
Check out our video below to hear an explanation from Immunis' science team on the results from Dr. Drummond's publication in GeroScience. You can also read the publication below.
Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secretome product derived from partially differentiated human pluripotent stem cells
Fix, Dennis K., Ziad S. Mahmassani, Jonathan J. Petrocelli, Naomi M.M.P. de Hart, Patrick J. Ferrara, Jessie S. Painter, Gabriel Nistor, Thomas E. Lane, Hans S. Keirstead, and Micah J. Drummond. “Reversal of Deficits in Aged Skeletal Muscle during Disuse and Recovery in Response to Treatment with a Secrotome Product Derived from Partially Differentiated Human Pluripotent Stem Cells.” GeroScience 43, no. 6 (December 1, 2021): 2635–52. https://doi.org/10.1007/s11357-021-00423-0.